Yan-Na Wang1,2,3,4, Xu-Jie Zhou1,2,3,4, Pei Chen5,2,3,4, Gui-Zhen Yu1,2,3,4, Xue Zhang5,2,3,4, Ping Hou1,2,3,4, Li-Jun Liu1,2,3,4, Su-Fang Shi5,2,3,4, Ji-Cheng Lv1,2,3,4, Hong Zhang5,2,3,4. 1. Renal Division, Peking University First Hospital, Beijing, China. 2. Peking University Institute of Nephrology, Beijing, China. 3. Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China. 4. Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China. 5. Renal Division, Peking University First Hospital, Beijing, China hongzh@bjmu.edu.cn.
Abstract
BACKGROUND: Galactose-deficient IgA1 plays a key role in the pathogenesis of IgA nephropathy, the most common primary GN worldwide. Although serum levels of galactose-deficient IgA1 have a strong genetic component, the genetic link between this molecule and IgA nephropathy has not yet been clearly established. METHODS: To identify novel loci associated with galactose-deficient IgA1, we performed a quantitative genome-wide association study for serum galactose-deficient IgA1 levels, on the basis of two different genome-wide association study panels conducted in 1127 patients with IgA nephropathy. To test genetic associations with susceptibility to IgA nephropathy, we also enrolled 2352 patients with biopsy-diagnosed IgA nephropathy and 2632 healthy controls. Peripheral blood samples from 59 patients and 27 healthy controls were also collected for gene expression analysis. RESULTS: We discovered two loci, in C1GALT1 and GALNT12, that achieved genome-wide significance, explaining about 3.7% and 3.4% of variance in serum galactose-deficient IgA1 levels, respectively. We confirmed the previously reported association of C1GALT1 with serum galactose-deficient IgA1 levels, but with a different lead single-nucleotide polymorphism (rs10238682; β=0.26, P=1.20×10-9); the locus we identified at GALNT12 (rs7856182; β=0.73, P=2.38×10-9) was novel. Of more interest, we found that GALNT12 exhibits genetic interactions with C1GALT1 in both galactose-deficient IgA1 levels (P=1.40×10-2) and disease risk (P=6.55×10-3). GALNT12 mRNA expression in patients with IgA nephropathy was significantly lower compared with healthy controls. CONCLUSIONS: Our data identify GALNT12 as a novel gene associated with galactose-deficient IgA1 and suggest novel genetic interactions. These findings support a key role of genetically conferred dysregulation of galactose-deficient IgA1 in the development of IgA nephropathy.
BACKGROUND: Galactose-deficient IgA1 plays a key role in the pathogenesis of IgA nephropathy, the most common primary GN worldwide. Although serum levels of galactose-deficient IgA1 have a strong genetic component, the genetic link between this molecule and IgA nephropathy has not yet been clearly established. METHODS: To identify novel loci associated with galactose-deficient IgA1, we performed a quantitative genome-wide association study for serum galactose-deficient IgA1 levels, on the basis of two different genome-wide association study panels conducted in 1127 patients with IgA nephropathy. To test genetic associations with susceptibility to IgA nephropathy, we also enrolled 2352 patients with biopsy-diagnosed IgA nephropathy and 2632 healthy controls. Peripheral blood samples from 59 patients and 27 healthy controls were also collected for gene expression analysis. RESULTS: We discovered two loci, in C1GALT1 and GALNT12, that achieved genome-wide significance, explaining about 3.7% and 3.4% of variance in serum galactose-deficient IgA1 levels, respectively. We confirmed the previously reported association of C1GALT1 with serum galactose-deficient IgA1 levels, but with a different lead single-nucleotide polymorphism (rs10238682; β=0.26, P=1.20×10-9); the locus we identified at GALNT12 (rs7856182; β=0.73, P=2.38×10-9) was novel. Of more interest, we found that GALNT12 exhibits genetic interactions with C1GALT1 in both galactose-deficient IgA1 levels (P=1.40×10-2) and disease risk (P=6.55×10-3). GALNT12 mRNA expression in patients with IgA nephropathy was significantly lower compared with healthy controls. CONCLUSIONS: Our data identify GALNT12 as a novel gene associated with galactose-deficient IgA1 and suggest novel genetic interactions. These findings support a key role of genetically conferred dysregulation of galactose-deficient IgA1 in the development of IgA nephropathy.
Authors: Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian Journal: J Am Soc Nephrol Date: 2008-02-13 Impact factor: 10.121
Authors: Kar Neng Lai; Sydney C W Tang; Francesco Paolo Schena; Jan Novak; Yasuhiko Tomino; Agnes B Fogo; Richard J Glassock Journal: Nat Rev Dis Primers Date: 2016-02-11 Impact factor: 52.329
Authors: Na Zhao; Ping Hou; Jicheng Lv; Zina Moldoveanu; Yifu Li; Krzysztof Kiryluk; Ali G Gharavi; Jan Novak; Hong Zhang Journal: Kidney Int Date: 2012-06-06 Impact factor: 10.612
Authors: E C Schofield; T Carver; P Achuthan; P Freire-Pritchett; M Spivakov; J A Todd; O S Burren Journal: Bioinformatics Date: 2016-04-08 Impact factor: 6.937
Authors: Krzysztof Kiryluk; Yifu Li; Zina Moldoveanu; Hitoshi Suzuki; Colin Reily; Ping Hou; Jingyuan Xie; Nikol Mladkova; Sindhuri Prakash; Clara Fischman; Samantha Shapiro; Robert A LeDesma; Drew Bradbury; Iuliana Ionita-Laza; Frank Eitner; Thomas Rauen; Nicolas Maillard; Francois Berthoux; Jürgen Floege; Nan Chen; Hong Zhang; Francesco Scolari; Robert J Wyatt; Bruce A Julian; Ali G Gharavi; Jan Novak Journal: PLoS Genet Date: 2017-02-10 Impact factor: 5.917
Authors: Krzysztof Kiryluk; Yifu Li; Francesco Scolari; Simone Sanna-Cherchi; Murim Choi; Miguel Verbitsky; David Fasel; Sneh Lata; Sindhuri Prakash; Samantha Shapiro; Clara Fischman; Holly J Snyder; Gerald Appel; Claudia Izzi; Battista Fabio Viola; Nadia Dallera; Lucia Del Vecchio; Cristina Barlassina; Erika Salvi; Francesca Eleonora Bertinetto; Antonio Amoroso; Silvana Savoldi; Marcella Rocchietti; Alessandro Amore; Licia Peruzzi; Rosanna Coppo; Maurizio Salvadori; Pietro Ravani; Riccardo Magistroni; Gian Marco Ghiggeri; Gianluca Caridi; Monica Bodria; Francesca Lugani; Landino Allegri; Marco Delsante; Mariarosa Maiorana; Andrea Magnano; Giovanni Frasca; Emanuela Boer; Giuliano Boscutti; Claudio Ponticelli; Renzo Mignani; Carmelita Marcantoni; Domenico Di Landro; Domenico Santoro; Antonello Pani; Rosaria Polci; Sandro Feriozzi; Silvana Chicca; Marco Galliani; Maddalena Gigante; Loreto Gesualdo; Pasquale Zamboli; Giovanni Giorgio Battaglia; Maurizio Garozzo; Dita Maixnerová; Vladimir Tesar; Frank Eitner; Thomas Rauen; Jürgen Floege; Tibor Kovacs; Judit Nagy; Krzysztof Mucha; Leszek Pączek; Marcin Zaniew; Małgorzata Mizerska-Wasiak; Maria Roszkowska-Blaim; Krzysztof Pawlaczyk; Daniel Gale; Jonathan Barratt; Lise Thibaudin; Francois Berthoux; Guillaume Canaud; Anne Boland; Marie Metzger; Ulf Panzer; Hitoshi Suzuki; Shin Goto; Ichiei Narita; Yasar Caliskan; Jingyuan Xie; Ping Hou; Nan Chen; Hong Zhang; Robert J Wyatt; Jan Novak; Bruce A Julian; John Feehally; Benedicte Stengel; Daniele Cusi; Richard P Lifton; Ali G Gharavi Journal: Nat Genet Date: 2014-10-12 Impact factor: 38.330
Authors: Taylor Person; R Glenn King; Dana V Rizk; Jan Novak; Todd J Green; Colin Reily Journal: J Interferon Cytokine Res Date: 2022-07-06 Impact factor: 3.657
Authors: Barbora Knoppova; Colin Reily; R Glenn King; Bruce A Julian; Jan Novak; Todd J Green Journal: J Clin Med Date: 2021-09-29 Impact factor: 4.241
Authors: Viktoria Dotz; Alessia Visconti; Hannah J Lomax-Browne; Florent Clerc; Agnes L Hipgrave Ederveen; Nicholas R Medjeral-Thomas; H Terence Cook; Matthew C Pickering; Manfred Wuhrer; Mario Falchi Journal: J Am Soc Nephrol Date: 2021-06-14 Impact factor: 14.978